Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)

The feasibility and effects of combination chemotherapy for very elderly patients with acute myeloid leukemia was examined in 65 patients (including previous myelodysplastic syndrome) aged 76 years or morewith a performance status of 0 - 3. Induction chemotherapy was performed with 30 mg m2 daunorub...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2006-10, Vol.47 (10), p.2062-2069
Main Authors: Mori, Mayumi, Ohta, Masatsugu, Miyata, Akira, Higashihara, Masaaki, Oshimi, Kazuo, Kimura, Hideo, Yagasaki, Fumiharu, Sunami, Kazutaka
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Aged
Aged, 80 and over
Antineoplastic Agents - pharmacology
behenoyl cytosine arabinoside
chemotherapy
Cytarabine - analogs & derivatives
Cytarabine - pharmacology
Disease-Free Survival
elderly
Female
Humans
Leukemia, Myeloid, Acute - therapy
Male
Remission Induction
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The feasibility and effects of combination chemotherapy for very elderly patients with acute myeloid leukemia was examined in 65 patients (including previous myelodysplastic syndrome) aged 76 years or morewith a performance status of 0 - 3. Induction chemotherapy was performed with 30 mg m2 daunorubicin on days 1 - 3, 150 mg m2 behenoyl cytosine arabinoside on days 1 - 7, and 70 mg m2 6-mercaptopurine with 300 mg allopurinol taken orally on days 1 - 7 (BHAC-DM). The complete remission (CR) rate was 38.5%, whereas overall survival at 2 and 5 years was 22.0% and 4.7%, respectively. Two- and 5-year survival of CR patients was 41.8% and 11.2%, respectively. The relapse rate of the 25 CR patients was 64.0% and disease-free survival at 2 and 5 years was 21.0% and 11.2%, respectively. The therapy-related mortality rate at induction was 13.8%. BHAC-DM is feasible and effective for selected very elderly acute myeloid leukemia patients.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190600733317